Liquid biopsies, in particular, analysis of cell-free DNA (cfDNA), have emerged as a
promising noninvasive diagnostic approach in oncology. Abnormal distribution of DNA …

In the era of precision medicine, it is crucial to identify molecular alterations that will guide
the therapeutic management of patients. In this context, circulating tumoral DNA (ctDNA) …

Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for
monitoring disease status of patients with advanced cancers. In melanoma, ctDNA has been …

In this article, we broadly review the application of cfDNA analysis to the diagnosis and
management of lymphoma. We introduce the advantages of cfDNA measurement over …

Epigenetic alterations are a common hallmark of human cancer. Single epigenetic markers
are starting to be incorporated into clinical practice; however, the translational use of these …

Purpose: Novel targeted and immunotherapies have improved outcomes in
relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but toxicities limit …

TP53 is mutated in 20–25% of aggressive B‐cell lymphoma (B‐NHL). To date, no studies
have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To …

The assessment of the cancer mutational profile is crucial for patient management,
stratification, and therapeutic decisions. At present, in hematological malignancies with a …

An elevated level of circulating cell-free DNA (cfDNA) has been associated with tumor bulk
and poor prognosis in diffuse large B-cell lymphoma (DLBCL), but the tumor-specific …

Solid tumors shed DNA into circulation, and there is growing evidence that the detection of
circulating tumor DNA (ctDNA) has broad clinical utility, including monitoring of disease …